What is Tandem Diabetes Care's D&A?

Tandem Diabetes Care (TNDM) reported D&A of $4.5M in Q1 2026.

How has Tandem Diabetes Care's D&A changed year-over-year?

Tandem Diabetes Care's D&A increased by 4.5% year-over-year, from $4.31M to $4.5M.

What is the long-term trend for Tandem Diabetes Care's D&A?

Over 4 years (2021 to 2025), Tandem Diabetes Care's D&A has grown at a 6.3% compound annual growth rate (CAGR), from $13.85M to $17.67M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Tandem Diabetes Care TNDM D&A

D&A at other companies

InsuletPODD

$26.2M+20.7%

MedtronicMDT

$716M-14.8%

AdaptHealthAHCO

$106.47M+12.9%

MannkindMNKD

$6.38M+203%

OmnicellOMCL

$18.57M-7.1%

ICU MedicalICUI

$50.03M+1.2%

Other financials

Income statement

See full

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Balance sheet

See full

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Cash flow

See full

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Valuation

See full

Market cap$1.03B-23.6%

Enterprise value$1.58B-11.3%

P/S1×-0.4×

Profitability

See full

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

FCF margin-0.8%-0.4pp

Returns & leverage

See full

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tandem Diabetes Care's D&A?: Tandem Diabetes Care (TNDM) reported D&A of $4.5M in Q1 2026.
How has Tandem Diabetes Care's D&A changed year-over-year?: Tandem Diabetes Care's D&A increased by 4.5% year-over-year, from $4.31M to $4.5M.
What is the long-term trend for Tandem Diabetes Care's D&A?: Over 4 years (2021 to 2025), Tandem Diabetes Care's D&A has grown at a 6.3% compound annual growth rate (CAGR), from $13.85M to $17.67M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.